FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383483832> ?p ?o ?g. }

• W4383483832 endingPage "718" @default.
• W4383483832 startingPage "709" @default.
• W4383483832 abstract "// Mark Chang 1 , Wolfram Samlowski 2 , 3 , 4 and Raul Meoz 2 , 3 1 University Medical Center of Southern Nevada, Las Vegas, NV 89102, USA 2 Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA 3 Department of Internal Medicine, University of Nevada, Las Vegas (UNLV), Las Vegas, NV 89102, USA 4 Department of Internal Medicine, University of Nevada, Reno, NV 89557, USA Correspondence to: Wolfram Samlowski, email: wsamlowski1@gmail.com Keywords: keratinocyte carcinoma; squamous cell skin cancer; cetuximab; epidermal growth factor receptor; radiation therapy Received: April 17, 2023     Accepted: June 19, 2023     Published: July 07, 2023 Copyright: © 2023 Chang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Background: Treatment for locally advanced cutaneous squamous cell cancers (laCSCC) remains poorly defined. Most laCSCC tumors express high levels of epidermal growth factor receptors (EGFR). Cetuximab has activity in other EGFR expressing cancers and enhances the effectiveness of radiotherapy. Methods: A retrospective review of institutional data identified eighteen patients with laCSCC treated with cetuximab induction and concurrent radiotherapy. The loading dose of cetuximab was 400 mg/m&#x00B2; IV. Subsequent weekly doses of 250 mg/m&#x00B2; IV were infused throughout the period of radiation. The treatment doses ranged from 4500&#x2013;7000 cGy, with a dose fraction of 200-250 cGy. Results: The objective response rate was 83.2% with 55.5% complete responses and 27.7% partial responses. Median progression-free survival was 21.6 months. Progression-free survival was 61% at 1 year and 40% at 2 years. With longer follow-up, some patients developed a local recurrence (16.7%), distant metastases (11.1%) or a second primary cancer (16.3%). Cetuximab was well tolerated, with 68.4% patients experienced only mild acneiform skin rash or fatigue (Grade 1 or 2). Radiotherapy produced expected side effects (skin erythema, moist desquamation, mucositis). Discussion: Cetuximab plus radiotherapy represents an active and tolerable treatment option for laCSCC, including patients with contraindications for checkpoint inhibitor therapy." @default.
• W4383483832 created "2023-07-08" @default.
• W4383483832 creator A5033252707 @default.
• W4383483832 creator A5047401461 @default.
• W4383483832 creator A5072377321 @default.
• W4383483832 date "2023-07-07" @default.
• W4383483832 modified "2023-10-01" @default.
• W4383483832 title "Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series" @default.
• W4383483832 cites W128632879 @default.
• W4383483832 cites W1490790087 @default.
• W4383483832 cites W1956371911 @default.
• W4383483832 cites W1988872599 @default.
• W4383483832 cites W1991185441 @default.
• W4383483832 cites W1998224687 @default.
• W4383483832 cites W1999794575 @default.
• W4383483832 cites W2005272660 @default.
• W4383483832 cites W2010927009 @default.
• W4383483832 cites W2031868047 @default.
• W4383483832 cites W2032344783 @default.
• W4383483832 cites W2057369727 @default.
• W4383483832 cites W2101157733 @default.
• W4383483832 cites W2108775833 @default.
• W4383483832 cites W2112875965 @default.
• W4383483832 cites W2124378780 @default.
• W4383483832 cites W2143902340 @default.
• W4383483832 cites W2151730005 @default.
• W4383483832 cites W2155384808 @default.
• W4383483832 cites W2155752258 @default.
• W4383483832 cites W2156272519 @default.
• W4383483832 cites W2170144295 @default.
• W4383483832 cites W2313276514 @default.
• W4383483832 cites W2579371903 @default.
• W4383483832 cites W2782712404 @default.
• W4383483832 cites W2792512660 @default.
• W4383483832 cites W2805968856 @default.
• W4383483832 cites W2809349532 @default.
• W4383483832 cites W2883883260 @default.
• W4383483832 cites W2902531676 @default.
• W4383483832 cites W2903859638 @default.
• W4383483832 cites W2940153447 @default.
• W4383483832 cites W3004267116 @default.
• W4383483832 cites W3035840030 @default.
• W4383483832 cites W3046607405 @default.
• W4383483832 cites W3200774211 @default.
• W4383483832 cites W4367590705 @default.
• W4383483832 doi "https://doi.org/10.18632/oncotarget.28470" @default.
• W4383483832 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37417890" @default.
• W4383483832 hasPublicationYear "2023" @default.
• W4383483832 type Work @default.
• W4383483832 citedByCount "1" @default.
• W4383483832 countsByYear W43834838322023 @default.
• W4383483832 crossrefType "journal-article" @default.
• W4383483832 hasAuthorship W4383483832A5033252707 @default.
• W4383483832 hasAuthorship W4383483832A5047401461 @default.
• W4383483832 hasAuthorship W4383483832A5072377321 @default.
• W4383483832 hasBestOaLocation W43834838321 @default.
• W4383483832 hasConcept C121608353 @default.
• W4383483832 hasConcept C126322002 @default.
• W4383483832 hasConcept C142724271 @default.
• W4383483832 hasConcept C143998085 @default.
• W4383483832 hasConcept C158739034 @default.
• W4383483832 hasConcept C2779438470 @default.
• W4383483832 hasConcept C2779998722 @default.
• W4383483832 hasConcept C2993101906 @default.
• W4383483832 hasConcept C502942594 @default.
• W4383483832 hasConcept C509974204 @default.
• W4383483832 hasConcept C526805850 @default.
• W4383483832 hasConcept C71924100 @default.
• W4383483832 hasConceptScore W4383483832C121608353 @default.
• W4383483832 hasConceptScore W4383483832C126322002 @default.
• W4383483832 hasConceptScore W4383483832C142724271 @default.
• W4383483832 hasConceptScore W4383483832C143998085 @default.
• W4383483832 hasConceptScore W4383483832C158739034 @default.
• W4383483832 hasConceptScore W4383483832C2779438470 @default.
• W4383483832 hasConceptScore W4383483832C2779998722 @default.
• W4383483832 hasConceptScore W4383483832C2993101906 @default.
• W4383483832 hasConceptScore W4383483832C502942594 @default.
• W4383483832 hasConceptScore W4383483832C509974204 @default.
• W4383483832 hasConceptScore W4383483832C526805850 @default.
• W4383483832 hasConceptScore W4383483832C71924100 @default.
• W4383483832 hasIssue "1" @default.
• W4383483832 hasLocation W43834838321 @default.
• W4383483832 hasLocation W43834838322 @default.
• W4383483832 hasOpenAccess W4383483832 @default.
• W4383483832 hasPrimaryLocation W43834838321 @default.
• W4383483832 hasRelatedWork W1971164957 @default.
• W4383483832 hasRelatedWork W1977855150 @default.
• W4383483832 hasRelatedWork W2016492905 @default.
• W4383483832 hasRelatedWork W2054822224 @default.
• W4383483832 hasRelatedWork W2110125130 @default.
• W4383483832 hasRelatedWork W2212264615 @default.
• W4383483832 hasRelatedWork W2277378171 @default.
• W4383483832 hasRelatedWork W2572564595 @default.
• W4383483832 hasRelatedWork W3028661725 @default.
• W4383483832 hasRelatedWork W4234363737 @default.
• W4383483832 hasVolume "14" @default.
• W4383483832 isParatext "false" @default.
• W4383483832 isRetracted "false" @default.

• next